ARCELLX ($ACLX) is expected to release its quarterly earnings data on Monday, May 18th after market close, per Finnhub. Analysts are expecting revenue of $7,650,000 and earnings of -$1.09 per share.
You can see Quiver Quantitative's $ACLX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARCELLX Insider Trading Activity
ARCELLX insiders have traded $ACLX stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $ACLX stock by insiders over the last 6 months:
- RAMI ELGHANDOUR (SEE REMARKS) sold 89,916 shares for an estimated $10,243,266
- MICHELLE GILSON (CHIEF FINANCIAL OFFICER) has made 0 purchases and 6 sales selling 30,894 shares for an estimated $2,634,304.
- CHRISTOPHER HEERY (CHIEF MEDICAL OFFICER) has made 0 purchases and 4 sales selling 19,790 shares for an estimated $1,314,095.
- DAVID CHARLES LUBNER sold 6,000 shares for an estimated $450,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ARCELLX Hedge Fund Activity
We have seen 152 institutional investors add shares of ARCELLX stock to their portfolio, and 144 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 3,444,350 shares (-96.7%) from their portfolio in Q1 2026, for an estimated $395,480,267
- VESTAL POINT CAPITAL, LP removed 2,925,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $335,848,500
- FIL LTD added 2,339,192 shares (+inf%) to their portfolio in Q1 2026, for an estimated $268,586,025
- HBK INVESTMENTS L P added 2,278,517 shares (+inf%) to their portfolio in Q1 2026, for an estimated $261,619,321
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,564,847 shares (-97.1%) from their portfolio in Q1 2026, for an estimated $179,675,732
- GLAZER CAPITAL, LLC added 1,507,128 shares (+inf%) to their portfolio in Q1 2026, for an estimated $173,048,436
- CITADEL ADVISORS LLC removed 1,478,417 shares (-98.5%) from their portfolio in Q1 2026, for an estimated $169,751,839
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ARCELLX Analyst Ratings
Wall Street analysts have issued reports on $ACLX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Wells Fargo issued a "Overweight" rating on 12/22/2025
To track analyst ratings and price targets for ARCELLX, check out Quiver Quantitative's $ACLX forecast page.
ARCELLX Price Targets
Multiple analysts have issued price targets for $ACLX recently. We have seen 13 analysts offer price targets for $ACLX in the last 6 months, with a median target of $115.0.
Here are some recent targets:
- Kelsey Goodwin from Guggenheim set a target price of $115.0 on 02/26/2026
- Michael Yee from UBS set a target price of $115.0 on 02/24/2026
- Geoff Meacham from Citigroup set a target price of $115.0 on 02/24/2026
- Daina Graybosch from Leerink Partners set a target price of $115.0 on 02/24/2026
- Stephen Willey from Stifel set a target price of $115.0 on 02/24/2026
- Asthika Goonewardene from Truist Securities set a target price of $120.0 on 02/24/2026
- Cory Kasimov from Evercore ISI Group set a target price of $115.0 on 02/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
